Skip to main content


Emerging agents and regimens for cancer therapy

This thematic series published in Journal of Hematology & Oncology will focus on novel agents, first-in-human studies, and regimens for different cancer types.

Fig. 2 from Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies; Dr. Wang et al.

  1. Content type: Review

    Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an incidence that increases with age, and a generally poor prognosis. The disease is clinically and genetically heterogene...

    Authors: Catherine Lai, Kimberley Doucette and Kelly Norsworthy

    Citation: Journal of Hematology & Oncology 2019 12:100

    Published on:

  2. Content type: Review

    The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly encountered ...

    Authors: Kevin Zarrabi, Azzam Paroya and Shenhong Wu

    Citation: Journal of Hematology & Oncology 2019 12:89

    Published on:

  3. Content type: Review

    Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improve...

    Authors: Sabarish Ayyappan and Kami Maddocks

    Citation: Journal of Hematology & Oncology 2019 12:82

    Published on:

  4. Content type: Review

    While promising, immunotherapy has yet to be fully unlocked for the preponderance of cancers where conventional chemoradiation reigns. This remains particularly evident in pediatric sarcomas where standard of ...

    Authors: Kyle A. Dyson, Brian D. Stover, Adam Grippin, Hector R. Mendez-Gomez, Joanne Lagmay, Duane A. Mitchell and Elias J. Sayour

    Citation: Journal of Hematology & Oncology 2019 12:78

    Published on:

  5. Content type: Review

    Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2). In c...

    Authors: Hui Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo and Yangfu Jiang

    Citation: Journal of Hematology & Oncology 2019 12:71

    Published on:

  6. Content type: Review

    Inflammation has long been accepted as a key component of carcinogenesis. During inflammation, inflammasomes are potent contributors to the activation of inflammatory cytokines that lead to an inflammatory cas...

    Authors: Shengchao Xu, Xizhe Li, Yuanqi Liu, Yu Xia, Ruimin Chang and Chunfang Zhang

    Citation: Journal of Hematology & Oncology 2019 12:64

    Published on:

  7. Content type: Review

    Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually re...

    Authors: Dwight H. Owen, Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David P. Carbone and Kai He

    Citation: Journal of Hematology & Oncology 2019 12:61

    Published on:

  8. Content type: Review

    Among all malignant tumors that threaten human health, virus-related tumors account for a large proportion. The treatment of these tumors is still an urgent problem to be resolved. The immune system is the “gu...

    Authors: Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma and Peng Wu

    Citation: Journal of Hematology & Oncology 2019 12:58

    Published on:

  9. Content type: Case report

    Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the pote...

    Authors: Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu and Weidong Han

    Citation: Journal of Hematology & Oncology 2019 12:57

    Published on:

  10. Content type: Review

    Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembroliz...

    Authors: Sen Yang, Zhe Zhang and Qiming Wang

    Citation: Journal of Hematology & Oncology 2019 12:47

    Published on:

  11. Content type: Review

    Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing r...

    Authors: Chao Zhang, Natasha B. Leighl, Yi-Long Wu and Wen-Zhao Zhong

    Citation: Journal of Hematology & Oncology 2019 12:45

    Published on:

  12. Content type: Review

    Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for severa...

    Authors: Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery and Haitao Zhao

    Citation: Journal of Hematology & Oncology 2019 12:42

    Published on:

  13. Content type: Review

    Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the pas...

    Authors: Hongbing Ma, Iyer Swaminathan Padmanabhan, Simrit Parmar and Yuping Gong

    Citation: Journal of Hematology & Oncology 2019 12:41

    Published on: